Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.

TitleOverexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.
Publication TypeJournal Article
Year of Publication2016
AuthorsMehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, Mucci LA, Chinnaiyan AM
JournalEur Urol
Volume70
Issue4
Pagination549-552
Date Published2016 10
ISSN1873-7560
KeywordsAged, Biomarkers, Tumor, Bone Neoplasms, Humans, In Situ Hybridization, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prostatectomy, Prostatic Neoplasms, PTEN Phosphohydrolase, RNA, Long Noncoding, Survival Rate
Abstract

The long noncoding RNA SChLAP1 is overexpressed in a subset of prostate cancers (PCa), and high SChLAP1 expression by in situ hybridization (ISH) independently predicts biochemical recurrence after radical prostatectomy. Importantly, although biochemical recurrence is a significant clinical outcome, it is not a validated surrogate for PCa-related mortality. Thus, we evaluated the association between SChLAP1 expression and development of lethal PCa in a large cohort of American men with PCa and long-term follow-up. SChLAP1 ISH was performed on tissue microarrays containing representative formalin-fixed, paraffin-embedded PCa tissue from all patients and scored using a semiquantitative method (ISH score range 0-400). Hazard ratios (HRs) for the association between SChLAP1 expression and time to development of lethal PCa were estimated using multivariable Cox regression analysis. Of the 937 patients evaluated, 89 (9.5%) had high SChLAP1 expression (ISH score ≥100), which in patients treated with radical prostatectomy was strongly associated with development of lethal PCa independent of age, Gleason score, pathologic stage, and PTEN status (HR 2.2, 95% confidence interval 1.1-4.1). These results suggest that SChLAP1 may be a useful tissue-based biomarker for identifying PCa patients at higher risk of lethal progression.

PATIENT SUMMARY: We examined expression of the RNA molecule SChLAP1 in a large group of prostate cancer patients with long-term follow-up and found that patients with high SChLAP1 expression had a significantly higher chance of developing lethal disease.

DOI10.1016/j.eururo.2015.12.003
Alternate JournalEur Urol
PubMed ID26724257
PubMed Central IDPMC4919276
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
P01 CA055075 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
R01 CA133891 / CA / NCI NIH HHS / United States
U01 CA113913 / CA / NCI NIH HHS / United States
UM1 CA167552 / CA / NCI NIH HHS / United States
P50 CA186786 / CA / NCI NIH HHS / United States
P50 CA069568 / CA / NCI NIH HHS / United States
R01 CA141298 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700